Citations 2
Specific Targeting of Human Interleukin (IL)-13 Receptor α2-Positive Cells with Lentiviral Vectors Displaying IL-13
Ou, Wu, Marino, Michael, Suzuki, Akiko , Joshi, Bharat , Husain, Syed R., Maisner, Andrea , Puri, Raj K. , Reiser, Jakob , Galanis, Evanthia
Human Gene Therapy Methods | September 15, 2012 | Volume: 23 | Issue: 2 | Pages: 137-147
Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors
Frecha, Cecilia , Costa, Caroline, Lévy, Camille , Négre, Didier , Russell, Stephen J. , Maisner, Andrea , Salles, Gilles , Peng, Kah-Whye , Cosset, François‐Loïc , Verhoeyen, Els , Russell, Stephen J , Salles, Gilles A
Blood | August 11, 2009 | Volume: 114 | Issue: 15 | Pages: 3173-3180
AbstractUp to now, no lentiviral vector (LV) tool existed to govern efficient and stable gene delivery into quiescent B lymphocytes, which hampers its application in gene therapy and immunotherapy areas. Here, we report that LVs incorporating measles virus (MV) glycoproteins, H and F, on their surface allowed transduction of 50% of quiescent B cells, which are not permissive to VSVG-LV transduction. This high transduction level correlated with B-cell SLAM expression and was not at cost of cell-cycle entry or B-cell activation. Moreover, the naive and memory phenotypes of transduced resting B cells were maintained. Importantly, H/F-LVs represent the first tool permitting stable transduction of leukemic cancer cells, B-cell chronic lymphocytic leukemia cells, blocked in G0/G1 early phase of the cell cycle. Thus, H/F-LV transduction overcomes the limitations of current LVs by making B cell–based gene therapy and immunotherapy applications feasible. These new LVs will facilitate antibody production and the study of gene functions in these healthy and cancer immune cells.